Johnson & Johnson $JNJ Stock Sold by Focused Investors LLC

Focused Investors LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 15.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 713,800 shares of the company’s stock after selling 134,000 shares during the period. Johnson & Johnson accounts for 7.8% of Focused Investors LLC’s investment portfolio, making the stock its biggest position. Focused Investors LLC’s holdings in Johnson & Johnson were worth $188,971,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Outlook Capital Management LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth about $28,000. Matrix Trust Co raised its position in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC bought a new position in Johnson & Johnson during the 2nd quarter valued at approximately $43,000. Hanseatic Management Services Inc. purchased a new stake in Johnson & Johnson in the 3rd quarter worth approximately $52,000. Finally, Polaris Financial Partners purchased a new stake in Johnson & Johnson in the 3rd quarter worth approximately $56,000. 69.55% of the stock is owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at TCT 2026 linked Impella-supported high-risk coronary procedures with lower mortality than prior study benchmarks; one report also cited a 94% procedural success rate. The findings could bolster the case for the heart-pump business, though further evidence, including the ongoing PROTECT IV trial, remains important. Article: Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Neutral Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors, but its alert provides no details about the claims or any legal action. The announcement alone does not establish wrongdoing or the likely financial impact. Article: Pomerantz Law Firm investigates claims on behalf of investors of Johnson & Johnson
• Negative Sentiment: The investor investigation is a potential source of uncertainty and could weigh on sentiment if it develops into substantive litigation or reveals material allegations. Article: Pomerantz Law Firm investigates claims on behalf of investors of Johnson & Johnson

Insider Activity

In other news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 64,515 shares of company stock worth $17,271,766. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 1.6%

JNJ stock opened at $266.10 on Wednesday. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.02. The business’s 50 day moving average price is $265.60 and its two-hundred day moving average price is $247.46. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The company has a market capitalization of $640.59 billion, a price-to-earnings ratio of 40.32, a price-to-earnings-growth ratio of 2.67 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on JNJ shares. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. Morgan Stanley dropped their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Bank of America reissued a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Finally, Guggenheim restated a “buy” rating and issued a $287.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $275.92.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.